Novoron Bioscience exploits the untapped potential of the LDL-receptor family to address devastating conditions such as dementia and spinal cord injury.

Platform in LDLR biology generating oral CNS drugs that block synaptic tau/α-syn spread (selective tau–LRP1). Multiple validated chemotypes; clean selectivity; early CNS fit; clear path to dev. candidate.